Research Article
Association of AGTR1 A1166C and CYP2C9∗3 Gene Polymorphisms with the Antihypertensive Effect of Valsartan
Table 3
Associations of gene polymorphisms and good response to valsartan treatment in the univariate and multivariate analyses.
| | | Unadjusted | Adjusted | | OR (95% CI) | | OR (95% CI) | |
| | AGTR1 | | | | | | AA | 1a | — | 1a | — | | AC + CC | 2.988 (1.340–6.661) | 0.007 | 2.764 (1.171–6.528) | 0.020 | | CYP2C9 | | | | | | ∗1/∗1 | 1a | — | 1a | — | | ∗1/∗3 | 0.607 (0.263–1.402) | 0.242 | 0.565 (0.222–1.438) | 0.231 | | Age | — | — | 1.035 (1.004–1.067) | 0.028 | | Gender | — | — | 0.776 (0.379–1.589) | 0.489 | | BMI | — | — | 1.000 (0.924–1.083) | 0.994 | | Grade of hypertension | | | | | | Grade 1 | — | — | 1a | — | | Grade 2 | — | — | 1.005 (0.408–2.475) | 0.991 | | Grade 3 | — | — | 0.513 (0.226–1.162) | 0.110 | | History of drinking | — | — | 0.650 (0.338–1.252) | 0.198 | | History of smoking | — | — | 0.752 (0.391–1.448) | 0.394 |
|
|
aReference category (odds ratio, 1). BMI: body mass index; CI: confidence interval; OR: odds ratio.
|
